Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022-2025) - PubMed
4 days ago
- #pharmacovigilance
- #incretin-therapies
- #gynecological-safety
- Comparative study on gynecological safety of tirzepatide (dual GIP/GLP-1 receptor agonist) vs. semaglutide (GLP-1 receptor agonist).
- Analysis based on FDA Adverse Event Reporting System (FAERS) data from Q1 2022 to Q3 2025.
- No significant difference in gynecological hemorrhagic events between tirzepatide (0.60%) and semaglutide (0.62%).
- Reporting odds ratio (ROR) for tirzepatide vs. semaglutide was 0.97 (95% CI = 0.82-1.14).
- 94.6% of tirzepatide reports were from consumers, compared to 53.4% for semaglutide.
- Findings suggest comparable safety profiles, but high consumer-driven reporting for tirzepatide warrants cautious interpretation.
- Future prospective studies needed to confirm findings in controlled clinical settings.